Program Book

Conclusions. During a ten-year period, 47 of 57 (82%) treated Group D
eyes were salvaged. 47% (27/57) were salvaged with systemic and local
chemotherapy alone. 20 of 57 (35%) eyes required IMRT for salvage.
In our series, systemic treatment for retinoblastoma even in advanced
eyes can salvage a majority of eyes, many with functional vision.
Financial disclosure. Doheny core grant support: NIH Grant EY03040 and Research to Prevent
Blindness
417 RBp120
THE FIRST EXPERIENCE OF RETINOBLASTOMA TREAT-
MENT WITH THE USE OF SUPERSELECTIVE INTRA-AR-
TERIAL CHEMOTHERAPY IN RUSSIA
S.V. Saakyan1 , S.B. Yakovlev2, G.L. Kobyakov2, N.K. Serova2, A. Jarwa1
(svsaakyan@yandex.ru)
1. Moscow Helmholtz Research Institute of Eye Diseases
2. Moscow Scientific Neurosurgery Institute named after Burdenko
Purpose. Evaluate the effectiveness of SSIAC in treatment of patients
with multifocal retinoblastoma with vitreal seeding.
Methods. 12 children of 1- 6 years of age with retinoblastoma of Stages
D and E, including 9 children with binocular retinoblastomas, were
managed. 10 patients underwent unsuccessful systemic chemotherapy
previously. On average 3 single injections of SSIAC using a 50 mg dose
of carboplatinum were conducted in each case.
Results. Preservation of 8 eyes was achieved with the use of SSIAC (1
eye in a patient with monocular retinoblastoma and 7 eyes in patients
with binocular retinoblastoma), resulting in 67% ocular preservation
rate. Observed findings included a decrease in prominension and
a development of calcifications in the main focus and the vitreal
seedings.
Conclusions. Conclusion: Our first experience demonstrated that SSIAC
allows for ocular preservation and improves the effectiveness of therapy
in children with advanced stages of retinoblastoma.
Financial disclosure. None
2317 RBp121
MISSING INTRAOCULAR BLUSH IN AN ANGIOGRAPHY
OF AN ADVANCED INTRAOCULAR RETINOBLASTOMA
M. Holdt, S. Göricke, E. Biewald, M. Schündeln, N. Bornfeld, M.
Schlamann (markus.holdt@uk-essen.de)
Department of Ophthalmology, Department of Radiology, Department
of Pediatric Oncology
Purpose. To find out therapeutical option for a single case with
advanced bilateral sporadic retinoblastoma (both eyes classified E)
Methods. In a case of a 13 month old girl with bilateral sporadic
retinoblastoma, both eyes were classified E (International Intraocular
Retinoblastoma Classification) or Vb (Reese-Ellsworth-Classification)
without light perception. All examinations including MRI showed no
extraocular pathology. The more affected eye was primary enucleated
without revealing histopathological risk factors. The attempt to
preserve the less affected eye with superselective ophthalmic artery
chemotherapy was discontinued due to not demarcated intraocular
blush beside expanded exophytic tumor masses with retinal
detachment. Angiography showed broad perfusion of periocular
tissues like lacrimal gland or nasal mucosa and a strong anastomosis
RETINOBLASTOMA
Posters
54
to anterior meningeal artery. This eye was also primary enucleated
without revealing histopathological risk factors. Hence no adjuvant
chemotherapy, no other therapy was necessary.
Results. The approach of superselective ophthalmic artery
chemotherapy has limitations when intraocular blush is not
definable.
Conclusions. Primary enucleation with histopathological confirmed
absence of risk factors still offers a therapy without any additional
burden in these rare cases with clinical advice for germline mutation.
Financial disclosure. None
2004 RBp122
CONSERVATIVE TREATMENT OF INTRAOCULAR
RETINOBLASTOMA: A PROSPECTIVE PHASE II TRIAL
FOR BILATERAL RETINOBLASTOMA WITH MACULAR
OR PARAMACULAR INVOLVEMENT
Christine Levy-Gabriel 1, Livia Lumbroso-Le Rouic 1, Isabelle Aerts 2,
David Hajaje3, Alexia Savignoni 3, Nathalie Algret 3, François Doz 2,
Laurence Desjardins 1 (christine.levy@curie.net)
1. Department of ocular oncology, Institut Curie
2. Department of oncologic pediatry, Institut Curie
3. Department of Biostatistics, Institut Curie, Paris France
Purpose. Intraocular retinoblastoma treatments often associate
chemotherapy and focal treatments. The protocols vary and may
combine two or three drugs, and different number of cycles associated
to the ocular treatments. In order to decrease the possible long term
sequels of laser scars for macular or paramacular tumors, a protocol of
laser reduction was initiated.
Methods. Monocentric prospective phase II study including children
with bilateral retinoblastoma and macular or paramacular involvement.
The protocol combines 6 cycles of of 3 drugs (vincristin carboplatin and
etoposide), diode laser thermotherapy sparing macula is associated
from the third cycle.
Results. 19 children, 23 eyes with 23 macular or paramacular tumors were
included in the study (July 2004-Sept 2009). Six tumors were treated
with chemotherapy alone, 2 of them presented a local recurrence. 17
tumors were treated with diode laser hyperthermy sparing macula, one
of them reccured. 20 eyes were salvaged without EBRT, 1 needed EBRT,
and 1 eye was enucleated
Conclusions. Six cycles of of 3 drugs (vincristin carboplatin and
etoposide) associated with diode laser thermotherapy sparing macula
achieves good local control while probably decreasing laser macular
scar. Visual function evolution will need longer follow-up.
Financial disclosure. None
1857 RBp123
EXTRACTION OF RADIATION-INDUCED CATARACT IN
PATIENTS WITH RETINOBLASTOMA
Z. Islamov, F. Islom (dr_islamov@yahoo.com)
National Center of Oncology, Uzbekistan
Mercer University, United States
Purpose. Analysis of Results of radiation-induced cataract extractions in
patients with retinoblastoma.